Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

Will Resubmit With New Data from Ongoing Studies

CAMBRIDGE, Mass., March 19 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) today announced the withdrawal of the European application to extend the Evoltra(R) (clofarabine) product label to include the treatment of elderly patients with acute myeloid leukemia (AML). This application and the data on which it was based were filed by Bioenvision, Ltd. before the company was acquired by Genzyme last year.

In a letter to the European Medicines Agency (EMEA) on behalf of Bioenvision, Genzyme states that the withdrawal is based on the EMEA's Committee for Medicinal Products for Human Use (CHMP) assessment that the data from the BIOV121 study are not sufficient to support a recommendation for market approval at this time. Bioenvision is now a wholly-owned subsidiary of Genzyme.

"As we expected, the filing that Bioenvision submitted to the EMEA was not sufficient to support approval in adult AML and our subsequent conversations with the CHMP have confirmed this assessment," stated Mark J. Enyedy, president of Genzyme Oncology, a business unit of Genzyme Corp. "We have engaged in a positive dialogue with the Rapporteurs regarding the requirements for approval and will develop a new submission to include data from one or more ongoing clinical studies of clofarabine in this patient population for submission possibly as early as the fourth quarter of this year."

In the United States, Genzyme has completed enrollment for a pivotal study in previously untreated, older adult patients with AML who are unlikely to benefit from standard intensive induction chemotherapy. Data from this study, known as CLASSIC II, are expected to provide substantial evidence for expa
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
(Date:1/14/2014)... Research Triangle Park, NC (PRWEB) January 14, 2014 ... diagnostic company focusing on ultra-sensitive POC diagnostic platforms and novel ... on their first round of financing netting a total of ... first outside equity capital in the company. This group of ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... 29 Reportlinker.com announces that a ... in its catalogue. , ... Broadening Market , ... diagnostic applications in the areas of ...
... Zealand, Oct. 29 ZyGEM Corp. Ltd., a provider ... life sciences applications, today announced it has entered into ... DNA extraction products to the Japanese market. This ... recent major distribution agreements for ZyGEM,s DNA extraction kits ...
... 29 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management ... Thursday, October 29 at 10:00 a.m. Pacific Time. , The conference is being ... presentation will be webcast live with slides and available for replay afterwards. The ... ...
Cached Biology Technology:Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 2Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 3Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 4Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 5Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 6ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 2ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 3ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 4
(Date:4/18/2014)... researchers have published soil organic carbon sequestration rates. ... organic carbon can be sequestered by simply switching from ... there is a growing body of research with evidence ... cover crops, small grains, and forages may not be ... , "Some studies have shown that both moldboard and ...
(Date:4/17/2014)... April 17 In the most densely forested and ... reflect two centuries of human needs, values and practices. ... clearing forests for agriculture and development, have set the ... U.S. Forest Service study reports. , The report ... and management needs in the Northern United States ...
(Date:4/17/2014)... West Orange, NJ. April 16, 2014. Kessler Foundation ... for $1.8 million from the Department of Defense ... PhD, is principal investigator for the randomized, double-blinded, ... to improve bone and muscle strength after spinal ... Human Performance & Engineering Research at Kessler Foundation. ...
Breaking Biology News(10 mins):Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2
... more about a tumor,s underlying biology, personalized medicine ... This year, the American Association for ... in Cancer Therapeutic Development: Challenges and Horizons conference ... Colo. This meeting regularly draws representatives from academia ...
... Pancreatic cancers use the sugar fructose, very common in ... drives cell division, helping the cancer to grow more quickly, ... has found. Although it,s widely known that cancers use ... the first time a link has been shown between fructose ...
... August 3rd, as part of the Ecological Society ... of scientists will discuss the environmental impacts of ... some of the most diverse habitats on the ... altered by mountaintop removal and valley fill mining. ...
Cached Biology News:Pancreatic cancers use fructose, common in the Western diet, to fuel their growth 2Pancreatic cancers use fructose, common in the Western diet, to fuel their growth 3Ecologists to discuss impacts of mountaintop mining at special ESA symposium 2Ecologists to discuss impacts of mountaintop mining at special ESA symposium 3
... Probes EnzChek Pyrophosphate Detection Kit,provides a ... measuring the inorganic pyrophosphate (PPi ) ... such as DNA and,RNA polymerizations, cyclic ... and the enzymatic activation of fatty ...
... is an intracellular marker normally present at ... subpopulation of bone marrow prelymphocytes. Elevated levels ... TdT cells are found to be associated ... of TdT thus provides a useful adjunct ...
... NOT FREEZE. Nuclear matrix proteins (NMPs) make up ... are associated with such functions as DNA replication, ... nuclear matrix has been shown to be highly ... known that cell death releases soluble nuclear matrix ...
Recombinant Cat Interferon Alpha Activity: 2.7 x 10 7 u/mg...
Biology Products: